Compare Merck & Co., Inc. (MRK) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while ProShares UltraPro Short QQQ ETF trades at $37.41. The key difference: Merck & Co., Inc. pays a 2.61% dividend while ProShares UltraPro Short QQQ ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SQQQ | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $131.84 | $92.95 |
52-Week Low | $77.60 | $36.31 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $37.32, down 1.11% amid a bearish technical signal with moving averages indicating selling pressure. The ETF is designed to deliver -3x the daily performance of the Nasdaq-100, making it highly sensitive to tech sector volatility. Recent news highlights its role as a tactical hedge tool but warns of significant long-term erosion due to daily reset mechanics.
The outlook for SQQQ remains high-risk, suitable only for short-term hedging against Nasdaq declines. Key risks include volatility decay from daily leverage and dependency on precise market timing. Investor sentiment is cautious, with analysts emphasizing its unsuitability as a long-term holding despite potential tactical opportunities during tech selloffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
